HUVECs-derived exosomes increase neovascularization and decrease limb necrosis in hindlimb ischemia

Muhamad T Ismail1, Dyah W Anggrahini1, Sofia M Haryana2

  • 1Department of Cardiology and Vascular Medicine, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia.

Narra J
|January 16, 2025
PubMed

Insights

Human umbilical vein endothelial cells (HUVECs)-derived exosomes significantly reduced amputation and necrosis in a hindlimb ischemia model. These exosomes promote neovascularization, offering a promising therapeutic strategy for peripheral arterial disease.

Area of Science:

  • Regenerative Medicine
  • Vascular Biology
  • Biotechnology

Background:

  • Chronic limb-threatening ischemia (CLTI) is a severe form of peripheral arterial disease (PAD) with high mortality and amputation rates.
  • Current revascularization treatments are insufficient for many CLTI patients, necessitating novel therapeutic approaches.
  • Exosomes derived from human umbilical vein endothelial cells (HUVECs) are being explored for their therapeutic potential.

Purpose of the Study:

  • To investigate the efficacy of HUVECs-derived exosomes in promoting neovascularization and reducing necrosis in a mouse hindlimb ischemia model.
  • To elucidate the underlying biological mechanisms of exosome-mediated therapeutic effects.

Main Methods:

  • An in vivo experimental study using a post-test-only control group design in BALB/c mice with unilateral double ligation of the hindlimb.
  • Groups included HUVECs-derived exosomes, conditioned media, phosphate-buffered saline (PBS), and a sham-operated control.
  • Assessment of capillary density, arteriole lumen diameter, clinical and histopathological necrosis, microRNA profiling, in silico analysis, and VEGF mRNA expression.

Main Results:

  • The exosome group showed no amputations, compared to 43% in the PBS group.
  • Significantly increased capillary density and arteriole lumen diameter were observed in the exosome group versus PBS and sham groups.
  • Reduced clinical and histopathological necrosis scores were noted in the exosome group compared to the PBS group.

Conclusions:

  • HUVECs-derived exosomes effectively improve neovascularization and decrease necrosis in a hindlimb ischemia model.
  • Potential mechanisms involve energy regulation, PI3K/AKT and TGF-β activation, the ubiquitin-proteasome system, and tyrosine kinase receptors.
  • Exosomes represent a promising cell-free therapeutic strategy for managing CLTI and PAD.